Multiple clinically relevant immunotherapies prolong the function of microencapsulated porcine islet xenografts in diabetic NOD mice without the use of anti-CD154 mAb.
adult porcine islets
diabetic NOD mice
immunosuppression
microencapsulation
xenografts
Journal
Xenotransplantation
ISSN: 1399-3089
Titre abrégé: Xenotransplantation
Pays: Denmark
ID NLM: 9438793
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
06
09
2019
revised:
06
12
2019
accepted:
09
12
2019
pubmed:
7
1
2020
medline:
17
8
2021
entrez:
7
1
2020
Statut:
ppublish
Résumé
Our goal was to identify clinically relevant immunotherapies that synergize with microencapsulation to protect adult porcine islet (API) xenografts in diabetic NOD mice. We have shown previously that dual costimulatory blockade (CTLA4-Ig plus anti-CD154 mAb) combined with encapsulation protects APIs long-term in NOD mice. Since no anti-CD154 mAbs currently are approved for use in humans, we tested the efficacy of other targeted immunosuppression regimens that might be used for diabetic patients receiving encapsulated islets. Microencapsulated APIs were transplanted i.p. in diabetic NOD mice given either no immunosuppression or combinations immunosuppressive reagents. Graft function was monitored by blood glucose levels, i.p. glucose tolerance tests, and histology. Mechanisms of rejection were investigated by phenotyping host peritoneal cells and measuring graft site cytokine and chemokine levels. New immunosuppressive therapies were compared to CTLA4-Ig plus anti-CD154 mAb, used here as a control. The most effective was triple treatment with CTLA4-Ig, anti-CD154 mAb, and intracapsular CXCL12, and the next most effective was a non-depleting anti-CD4 mAb (YTS177.9) plus intracapsular CXCL12. Three additional regimens (CTLA4-Ig plus YTS177.9, YTS177.9 alone, and anti-OX40-Ligand mAb alone) significantly prolonged encapsulated API function. Dual treatment with CTLA4-Ig plus anti-CD40 mAb was as effective as CTLA4-Ig plus anti-CD154 mAb. Five other monotherapies and three combination therapies did not augment encapsulated API survival. Most peritoneal cytokines and chemokines were either absent or minimal. At necropsy, the capsules were intact, not fibrosed, and clean when function was maintained, but were coated with host cells if rejection had occurred. Multiple different immunotherapies which specifically inhibit CD4
Sections du résumé
BACKGROUND
Our goal was to identify clinically relevant immunotherapies that synergize with microencapsulation to protect adult porcine islet (API) xenografts in diabetic NOD mice. We have shown previously that dual costimulatory blockade (CTLA4-Ig plus anti-CD154 mAb) combined with encapsulation protects APIs long-term in NOD mice. Since no anti-CD154 mAbs currently are approved for use in humans, we tested the efficacy of other targeted immunosuppression regimens that might be used for diabetic patients receiving encapsulated islets.
METHODS
Microencapsulated APIs were transplanted i.p. in diabetic NOD mice given either no immunosuppression or combinations immunosuppressive reagents. Graft function was monitored by blood glucose levels, i.p. glucose tolerance tests, and histology. Mechanisms of rejection were investigated by phenotyping host peritoneal cells and measuring graft site cytokine and chemokine levels.
RESULTS
New immunosuppressive therapies were compared to CTLA4-Ig plus anti-CD154 mAb, used here as a control. The most effective was triple treatment with CTLA4-Ig, anti-CD154 mAb, and intracapsular CXCL12, and the next most effective was a non-depleting anti-CD4 mAb (YTS177.9) plus intracapsular CXCL12. Three additional regimens (CTLA4-Ig plus YTS177.9, YTS177.9 alone, and anti-OX40-Ligand mAb alone) significantly prolonged encapsulated API function. Dual treatment with CTLA4-Ig plus anti-CD40 mAb was as effective as CTLA4-Ig plus anti-CD154 mAb. Five other monotherapies and three combination therapies did not augment encapsulated API survival. Most peritoneal cytokines and chemokines were either absent or minimal. At necropsy, the capsules were intact, not fibrosed, and clean when function was maintained, but were coated with host cells if rejection had occurred.
CONCLUSIONS
Multiple different immunotherapies which specifically inhibit CD4
Substances chimiques
CD40 Ligand
147205-72-9
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e12577Informations de copyright
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Shapiro AM, Ricordi C, Hering BJ, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med. 2006;355:1318-1330.
Leitão CB, Cure P, Tharavanij T, Baidal DA, Alejandro R. Current challenges in islet transplantation. Curr Diab Rep. 2008;8:324-331.
Mourad NI, Gianello PR. Xenoislets: porcine pancreatic islets for the treatment of type I diabetes. Curr Opin in Organ Transplant. 2017;22(6):529-534.
Kapp JA, Whiteley PJ. Insulin-determinant recognition by helper and suppressor T cells. Chem Immunol. 1989;46:85-100.
Wright AD, Walsh CH, Fitzgerald MG, Malins JM. Very pure porcine insulin in clinical practice. Br Med J. 1979;1:25-27.
Kannan PS, Martin B, Turgeon NA, Kirk AD. Islet cell xenotransplantation: A serious look towards the clinic. Xenotransplantation. 2014;21:221-229.
Cui H, Tucker-Burden C, Cauffiel SMD, et al. Long-term metabolic control of autoimmune diabetes in spontaneously diabetic NOD mice by non-vascularized microencapsulated adult porcine islets. Transplantation. 2009;88:160-169.
Gill RG, Wolf L. Immunobiology of cellular transplantation. Cell Transplant. 1995;4:361-370.
Black SP, Constantinidis I, Cui H, Tucker-Burden C, Weber CJ, Safley SA. Immune responses to an encapsulated allogeneic β-cell line in diabetic NOD mice. Biochem Biophys Res Commun. 2006;340:236-243.
Weber CJ, Zabinski S, Koschitzky T, et al. The role of CD4+ helper T cells in the destruction of microencapsulated islet xenografts in NOD mice. Transplantation. 1990;49:396-404.
Weber CJ, Safley SA, Hagler MK, Kapp JA. Evaluation of graft-host response for various tissue sources and animal models. Ann N Y Acad Sci. 1999;875:233-254.
Weber CJ, Hagler MK, Chryssochoos JT, et al. CTLA4-Ig prolongs survival of microencapsulated rabbit islet xenografts in spontaneously diabetic NOD mice. Transplant Proceed. 1996;28(2):821-823.
Weber CJ, Kapp JA, Hagler MK, Safley SA, Chryssochoos JT, Chaikof EL. Long-term survival of poly-l-lysine-alginate microencapsulated islet xenografts in spontaneously diabetic NOD mice. In: Kühtreiber WM, Lanza RP, Chick WL, eds. Cell Encapsulation Technology and Therapeutics. Boston: Birkhäuser; 1999:117-137.
Gill R, Wolf L, Daniel D, Coulonbe M. CD4+ T cells are both necessary and sufficient for islet xenograft rejection. Transplant Proc. 1994;26:1203-1204.
Harding F, McArthur J, Gross J, Raulet D, Allison J. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature. 1992;356:607-609.
Freeman GJ, Boussiotis VA, Anumanthan A, et al. B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity. 1995;2:523-532.
Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med. 2000;6:114.
Lu X, Borel JF. Requirement of CD4 cells for induction and maintenance of unresponsiveness in islet xenografted mice. Xenotransplantation. 1998;5:207-214.
Diz R, Garland A, Vincent BG, et al. Autoreactive effector/memory CD4+ and CD8+ T cells infiltrating grafted and endogenous islets in diabetic NOD mice exhibit similar T cell receptor usage. PLoS ONE. 2012;7:e52054.
Croft M, So T, Duan W, Soroosh P. The significance of OX40 and OX40L to T cell biology and immune disease. Immunol Rev. 2009;229:173-191.
Yusuf-Makagiansar H, Anderson ME, Yakovleva TV, Murray JS, Siahaan TJ. Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases. Med Res Rev. 2002;22:146-167.
Alagpulinsa DA, Cao JJL, Driscoll RK, et al. Alginate-microencapsulation of human stem cell-derived β cells with CXCL12 prolongs their survival and function in immunocompetent mice without systemic immunosuppression. Am J Transplant. 2019;19:1930-1940.
Chen T, Yuan J, Duncanson S, et al. Alginate encapsulant incorporating CXCL12 supports long-term allo- and xenoislet transplantation without systemic immune suppression. Am J Transplant. 2015;15:618-627.
Abrams JR, Lebwohl MG, Guzzo CA, et al. CTLA4-Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest. 1999;103:1243-1252.
Holdcraft RW, Gazda LS, Circle L, et al. Enhancement of in vitro and in vivo function of agarose-encapsulated porcine islets by changes in the islet microenvironment. Cell Transplant. 2014;23:929-944.
Safley SA, Kenyon NS, Berman DM, et al. Microencapsulated adult porcine islets transplanted intraperitoneally in streptozotocin-diabetic non-human primates. Xenotransplantation. 2018;25(6):e12450.
Fritschy WM, van Straaten JFM, de Vos P, et al. The efficacy of intraperitoneal pancreatic islet isografts in the reversal of diabetes in rats. Transplantation. 1991;52:777-783.
Safley SA, Kapp LM, Tucker-Burden C, Hering B, Kapp JA, Weber CJ. Inhibition of cellular immune responses to encapsulated porcine islet xenografts by simultaneous blockade of two different costimulatory pathways. Transplantation. 2005;79:409-418.
Friedman T, Smith RN, Colvin RB, Lacomini J. A critical role for human CD4 T-cells in rejection of porcine islet cell xenografts. Diabetes. 1999;48:2340-2348.
Kobayashi T, Harb G, Rajotte RV, et al. Immune mechanisms associated with the rejection of encapsulated neonatal porcine islet xenografts. Xenotransplantation. 2006;13(6):547-559.
Arefanian H, Tredget EB, Rajotte RV, et al. Combination of anti-CD4 with anti-LFA-1 and anti-CD154 monoclonal antibodies promotes long-term survival and function of neonatal porcine islet xenografts in spontaneously diabetic NOD mice. Cell Transplant. 2007;16(8):787-798.
Graca L, Le Moine A, Lin CY, Fairchild PJ, Cobbold SP, Waldmann H. Donor-specific transplantation tolerance: The paradoxical behaviour of CD4+ CD25+ T cells. PNAS. 2004;101:10122-10126.
Lu X, Schultz M, Zihlmann HR, Hans R, Borel JR. Long-term survival of hamster islet xenografts in mice under short-course treatment with nondepleting versus depleting anti-CD4 monoclonal antibodies. Xenotransplantation. 1998;5:154-163.
Larsen C, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature. 1996;381:434-438.
Judge TA, Wu Z, Zheng XG, Sharoe AH, Sayegh MH, Turka LA. The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival. J Immunol. 1999;162:1947-1951.
Gilson CR, Milas Z, Gangappa S, et al. Anti-CD40 monoclonal antibody synergizes with CTLA4-Ig in promoting long-term graft survival in murine models of transplantation. J Immunol. 2009;183:1625-1635.
Rabinovitch A, Sumoski W, Rajotte RV, Warnock GL. Cytotoxic effects of cytokines on human pancreatic islet cells in monolayer culture. J Clin Endocrinol Metab. 1990;71:152-156.
Simeonovic CJ, Townsend MJ, Karupiah G, et al. Analysis of the Th1/Th2 paradigm in transplantation: interferon-gamma deficiency converts Th1-type proislet allograft rejection to a Th2-type xenograft-like response. Cell Transplant. 1999;8:365-373.
Krook H, Hagberg A, Song Z, Landegren U, Wennberg L. A distinct Th1 immune response precedes the described Th2 response in islet xenograft rejection. Diabetes. 2002;51:79-86.
Carr MW, Roth SJ, Luther E, Rose SS, Springer TA. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. PNAS. 1994;91:3652-3656.
Weber CJ, Hagler MK, Chryssochoos JT, et al. CTLA4-Ig prolongs survival of microencapsulated neonatal porcine islet xenografts in diabetic NOD mice. Cell Transplant. 1997;6:505-508.
Winsor-Hines D, Merrill C, O'Mahony M, et al. Induction of immunological tolerance/hyporesponsiveness in baboons with a nondepleting CD4 antibody. J Immunol. 2004;173:4715-4723.
Liu W, Wei X, Li L, et al. CCR4 mediated chemotaxis of regulatory T cells suppress the activation of T cells and NK cells via TGF-ß pathway in human non-small cell lung cancer. Biochem Biophys Res Commun. 2017;488:196-203.
Kim YH, Duvic M, Obitz E, et al. Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood. 2007;109:4655-4662.
Léger OJ, Yednock TA, Tanner L, et al. Humanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis. Hum Antibodies. 1997;8:3-16.
Gauvreau GM, Bouet L-P, Cockcroft DW, et al. OX40L blockade and allergen-induced airway responses in subjects with mild asthma. Clin Exp Allergy. 2013;44:29-37.